MR-proADM 可预测 ATTR 心脏淀粉样变性患者的死亡与心衰事件
研究在西班牙 337 例 ATTR-CM 患者中评估 12 种循环生物标志物的预后价值,并在美国 210 例及 ATTR-ACT 试验 416 例两个外部队列中验证。中位随访 19.7 个月,MR-proADM 预后判别能力最强,阈值为 1.1 nmol/L,加入三种分期系统均改善死亡预测。
要点
- MR-proADM 在 12 种生物标志物中预后判别能力最强。
- MR-proADM ≥1.1 nmol/L 为最佳预后阈值,两个外部队列均显示结局更差。
- 加入 MR-proADM 可改善 National Amyloid Center、Mayo 与 Columbia 分期系统的死亡预测。
核心结论
- 在 ATTR-CM 患者中,MR-proADM 水平与疾病严重程度相关并提示更差预后。
- MR-proADM 改善全因死亡预测并可捕捉心力衰竭事件。
研究设计与样本
- 研究纳入西班牙 337 例 ATTR-CM 患者,评估 12 种循环生物标志物,采用 Cox 模型确定预测能力。
- 结果在美国 210 例患者及 ATTR-ACT 试验 416 例患者的两个独立外部队列中验证。
主要发现
- 中位随访 19.7 个月(IQR,6.5-42.3),67 例(19.9%)死亡或接受心脏移植,81 例(24%)发生心力衰竭事件。
- MR-proADM 对全因死亡的 C-index 为 0.788(95%CI,0.723-0.851),对死亡与心衰事件复合终点为 0.721(95%CI,0.669-0.772)。
- MR-proADM 与 ATTR-CM 多项严重程度参数相关,并独立关联死亡、心衰事件及复合终点。
- 两个验证队列中 MR-proADM ≥1.1 nmol/L 者结局更差(P<0.001),在接受 tafamidis 的患者中亦得到确认。
关键数值与推荐
- MR-proADM ≥1.1 nmol/L 被确定为最佳预后阈值。
- 加入 MR-proADM 后,National Amyloid Center 系统 AUC 由 0.682 升至 0.737(P<0.001)。
- 加入 MR-proADM 后,Mayo 系统 AUC 由 0.659 升至 0.749(P<0.001)。
- 加入 MR-proADM 后,Columbia 系统 AUC 由 0.699 升至 0.768(P<0.001)。
临床怎么用
- 对 ATTR-CM 患者可检测 MR-proADM,以 1.1 nmol/L 为界辅助识别高危人群。
- 可将 MR-proADM 与现有分期系统联合使用,提升死亡风险预测。
- MR-proADM 升高提示关注心衰事件风险,包括正在接受 tafamidis 治疗者。
局限性
- 原文摘要未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With the increasing diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) at earlier stages and new therapies, there is a rising demand for tools to stratify risk and prognosis. We evaluated the prognostic value of multiple circulating biomarkers for predicting outcomes in ATTR-CM. METHODS: We evaluated 12 different circulating biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin I [hsTnI], mid-regional pro-adrenomedullin [MR-proADM], carbohydrate antigen 125 [CA125], soluble suppressor of tumorigenicity 2 [sST2], cluster of differentiation antigen 146 [CD146], growth/differentiation factor-15 [GDF-15], alpha-klotho, fibroblast growth factor 23 [FGF-23], galectin-3, insulin-like growth factor-binding protein 7 [IGFBP-7], and estimated glomerular filtration rate [eGFR]) in 337 ATTR-CM patients from Spain. Cox models were employed to determine their predictive abilities. Findings were validated in 2 independent external cohorts of 210 patients from the United States and 416 patients from the ATTR-ACT trial, respectively. RESULTS: Over a median follow-up of 19.7 months (IQR, 6.5-42.3), 67 patients (19.9%) died/underwent heart transplantation, and 81 (24%) had heart failure events. MR-proADM was the biomarker with the strongest prognostic performance, with a C-index of 0.788 (95% CI, 0.723-0.851) for all-cause mortality and 0.721 (95% CI, 0.669-0.772) for the composite endpoint of death and heart failure events. MR-proADM was associated with multiple parameters of ATTR-CM severity and was independently associated with mortality, heart failure events, and the composite endpoint. MR-proADM ≥1.1 nmol/L was identified as the optimal prognostic threshold, and it improved prediction of mortality when added to the National Amyloid Center (area under the curve [AUC], 0.682 versus 0.737; P<0.001), Mayo (AUC, 0.659 versus 0.749; P<0.001), and the Columbia staging systems (AUC, 0.699 versus 0.768; P<0.001). In both validation cohorts, patients with MR-proADM ≥1.1 nmol/L had worse outcomes (P<0.001). This association was also confirmed in patients receiving tafamidis. CONCLUSIONS: In patients with ATTR-CM, MR-proADM levels are associated with disease severity and worse prognosis. MR-proADM improves prediction of all-cause mortality and captures heart failure events.
引用
- Peiró-Aventín B, Revuelta-Lopez E, Brandao M, et al. MR-ProADM Predicts Mortality and Heart Failure Events in ATTR Cardiac Amyloidosis. Circulation. 2026. PMID: 41914183. doi:10.1161/CIRCULATIONAHA.125.077833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。